



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 09/01/2023 08:46 Received: 09/01/2023 08:46

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: Chromogranin A, Serum, 53, 0-103, ng/mL, ARRL

INTERPRETIVE INFORMATION: Chromogranin A, Serum

This test is performed using the BRAHMS CGA II Kryptor kit. Results obtained with different methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Nontumor-related elevations of Chromogranin A can be observed in gastrointestinal, cardiovascular, and renal disorders, as well as with proton pump inhibitor (PPI) therapy. It is recommended to stop PPI treatment for at least two weeks prior to testing. Moderate H2-receptor antagonist therapy does not lead to significant elevations of Chromogranin A.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes. Performed by ARUP Laboratories, 500 Chipeta Way, SLC, UT 84108 800-522-2787 www.aruplab.com, Julio Delgado, MD, Lab. Director CLIA Number: 46D0523979

Performing Site:

ARRL: ARUP REFERENCE LAB 500 Chipeta Way Salt Lake City UT 841081221

Reported Date: 2023.09.01 8:46

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED